Nephron. Clinical practice · 2009
Transforming growth factor-beta 1 in Balkan endemic nephropathy.
Сравнительное исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dukanović Ljubica, Lezaić Visnja, Miljković Dorde, Momcilović Miljana, Bukvić Danica, Marić Ivko, Miljković Zeljka, Marinković Jelena, Mostarica-Stojković Marija
Аннотация
BACKGROUND/AIM: The aim of this study was to compare plasma and urine transforming growth factor-beta1 (TGF-beta1) levels in patients with different stages of Balkan endemic nephropathy (BEN) with those in patients with primary glomerulonephritis (GN) and healthy controls.
METHODS: The study involved 47 patients with BEN (30 with manifest BEN and 17 in the early stage of BEN), 12 patients with GN and 10 healthy controls. Plasma and urine TGF-beta1 was assayed by enzyme-linked immunosorbent assay.
RESULTS: The median plasma TGF-beta1 levels differed nonsignificantly between the groups (4,908-6,442 pg/ml), but individual plasma TGF-beta1 levels in BEN patients exhibited the highest dispersion. Median urinary TGF-beta1 excretion (pg/mg creatinine) was significantly higher in patient groups (manifest BEN: 203, early-stage BEN: 341, GN: 775) than in healthy controls (42). No correlation was found between plasma and urine TGF-beta1 levels or between plasma TGF-beta1 levels and creatinine clearance for any of the examined groups.
CONCLUSION: Plasma TGF-beta1 levels in BEN patients extended over the widest range, but no significant differences were found between the median values for the groups. Median urinary TGF-beta1 excretion was significantly higher in patients with BEN and GN than in healthy controls.
METHODS: The study involved 47 patients with BEN (30 with manifest BEN and 17 in the early stage of BEN), 12 patients with GN and 10 healthy controls. Plasma and urine TGF-beta1 was assayed by enzyme-linked immunosorbent assay.
RESULTS: The median plasma TGF-beta1 levels differed nonsignificantly between the groups (4,908-6,442 pg/ml), but individual plasma TGF-beta1 levels in BEN patients exhibited the highest dispersion. Median urinary TGF-beta1 excretion (pg/mg creatinine) was significantly higher in patient groups (manifest BEN: 203, early-stage BEN: 341, GN: 775) than in healthy controls (42). No correlation was found between plasma and urine TGF-beta1 levels or between plasma TGF-beta1 levels and creatinine clearance for any of the examined groups.
CONCLUSION: Plasma TGF-beta1 levels in BEN patients extended over the widest range, but no significant differences were found between the median values for the groups. Median urinary TGF-beta1 excretion was significantly higher in patients with BEN and GN than in healthy controls.